Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY: BLCO )

15.86 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Barclays Maintains Equal-Weight Rating for Bausch & Lomb: Here's What You Need To Know
Via Benzinga
Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
From Bausch + Lomb Corporation
Via Business Wire
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Bausch & Lomb Earnings Preview
Via Benzinga
The Latest Analyst Ratings for Bausch & Lomb
Via Benzinga
Bausch & Lomb Earnings Preview
Via Benzinga
Eye Care-Focused Bausch + Lomb's Stock Surges On Upbeat Annual Guidance Despite Deeper Losses
Bausch + Lomb achieves Q4 2023 sales of $1.173 billion, exceeding expectations with an 18% YoY growth. CEO Brent Saunders anticipates robust growth in 2024, projecting sales of $4.6-$4.7 billion and an... 
Via Benzinga
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
From Emergent BioSolutions
Via GlobeNewswire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
6 Analysts Have This to Say About Bausch & Lomb
Via Benzinga
Wall Street Waits With Bated Breath For Nvidia Earnings After Tech Selloff, Fed Minutes Eyed: Analyst Flags This As Biggest Risk For Market
The market will broaden the sustenance of its rally when interest-rate cuts begin to be priced in and investors begin to think about the roadmap, an analyst said. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... 
Via Benzinga
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting
From Bausch + Lomb
Via Business Wire
Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy... 
Via Benzinga
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Completes Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.